# CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 21-449

**CHEMISTRY REVIEW(S)** 





## NDA 21-449

Adefovir Dipivoxil

Gilead Science, Inc.

Ko-Yu Lo, Ph.D. Division of Antiviral Drug Products



Chemistry Review Data Sheet

## CEPACION CONTROL OF THE CONTROL OF T

## **Chemistry Review Data Sheet**

- 1. NDA # 21-449
- 2. REVIEW # 1
- 3. REVIEW DATE: 9/17/2002
- 4. REVIEWER: Ko-Yu Lo, Ph.D.
- 5. PREVIOUS DOCUMENTS:

**Previous Documents** 

**Document Date** 

N/A

#### 6. SUBMISSION(S) BEING REVIEWED:

Amendment BZ Amendment BL Amendment BL Amendment BL Amendment BZ 22 23 24 25 26 27 27 28 29 20 20 20 20 20 20 20 20 20 20 20 20 20	1/MAR/2002 9/MAY/2002 2/JUN/2002 9/AUG/2002 3/AUG/2002 9/AUG/2002
	1/SEP/2002

#### 7. NAME & ADDRESS OF APPLICANT:

Name:

Gilead Sciences, Inc.

#### **CHEMISTRY REVIEW**



Chemistry Review Data Sheet

Address:

333 Lakeside Drive Foster City, CA 94404

Representative:

Martine Kraus, Ph.D.

Telephone:

650-522-5722

#### 8. DRUG PRODUCT NAME/CODE/TYPE:

- a) Proprietary Name: HEPSERA<sup>TM</sup>
- b) Non-Proprietary Name (USAN): Adefovir Dipivoxil
- c) Code Name/# (ONDC only): GS-0840
- d) Chem. Type/Submission Priority (ONDC only):
  - Chem. Type: 1
  - Submission Priority: P
- 9. LEGAL BASIS FOR SUBMISSION: N/A
- 10. PHARMACOL. CATEGORY: Antiviral
- 11. DOSAGE FORM: Tablet
- 12. STRENGTH/POTENCY: 10 mg
- 13. ROUTE OF ADMINISTRATION: Oral
- 14. Rx/OTC DISPENSED: X Rx OTC
- 15. <u>SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM)[Note27]:</u>

\_\_\_\_SPOTS product – Form Completed

X\_Not a SPOTS product





Chemistry Review Data Sheet

## 16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

9-[2-[[bis[(pivaloyloxy)methoxy]phosphinyl]methoxy]ethyl]adenine (IUPAC) Propanoic acid, 2,2-dimethyl-, [[[2-(6-amino-9H-purine-9-yl)ethoxy]methyl]-phosphinylidene]bis(oxymethylene)ester (CAS)

CAS Reg. No.

142340-99-6

Synonym:

bis-POM PMEA

Molecular formula

 $C_{20}H_{32}N_5O_8P$ 

Molecular weight

501.48

Structure formula

## 17. RELATED/SUPPORTING DOCUMENTS:

#### A. DMFs:

DMF#	ТҮРЕ	HOLDER	ITEM REFERENCED	CODE <sup>1</sup>	STATUS <sup>2</sup>	DATE REVIEW COMPLETED	COMMENTS
_	III			4	N/A		
_ \							
				·		Sec. por	
	Ш	·		3	Adequate	12/15/1999	
	III	"		4	N/A		
<b> </b>		-					
	III			4	N/A		
L_I	III			3	Adequate	3/2/2000	



#### **CHEMISTRY REVIEW**



#### Chemistry Review Data Sheet

	T	-	<b>-</b>	Τ	T	110/20/2001	T 1
<u> </u>				<u> </u>		10/30/2001	
-	III			3 7	Adequate Adequate	2/28/2000	
	7				·		
	III			3	Adequate	5/11/2000	
	III			3	Adequate	9/10/1997	
	ļ				l		
	III			3	Adequate	10/4/2001	·
	III			3	Adequate Adequate	4/13/2000 1/12/2001	
	III			4	N/A		( the state of the

<sup>&</sup>lt;sup>1</sup> Action codes for DMF Table:

1 - DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

- 2-Type 1 DMF
- 3 Reviewed previously and no revision since last review
- 4 Sufficient information in application
- 5 Authority to reference not granted
- 6 DMF not available
- 7 Other (explain under "Comments")

#### **B.** Other Documents:

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
IND		Adeforvir Dipivoxil
IND		Adefovir Dipivoxil
NDA		Adefovir Dipivoxil Tablets
		(30, 60 & 120 mg)

<sup>&</sup>lt;sup>2</sup> Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)



#### **CHEMISTRY REVIEW**



Chemistry Review Data Sheet

## 18. STATUS:

CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biometrics	N/A		
EES	Acceptable	9/9/2002	(HFD-322)
Pharm/Tox	Impurity levels qualification adequate	9/9/2002	Peter Verma
Biopharm	Dissolution specification acceptable	9/9/2002	Robert Kumi
LNC	N/A		
Methods Validation	Pending		
OPDRA	Acceptable		
EA	Exclusion Acceptable		
Microbiology	N/A		

APPEARS THIS WAY ON ORIGINAL

9

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Ko-yu Lo 9/23/02 12:41:23 PM CHEMIST

Stephen Paul Miller 9/23/02 12:51:30 PM CHEMIST

2

#### FDA CDER EES ESTABLISHMENT EVALUATION REQUEST SUMMARY REPORT

Application:

NDA 21449/000 .

Priority: P

Org Code: 530

Stamp: 21-MAR-2002 Regulatory Due: 21-SEP-2002

FOSTER CITY, CA 94404

**Action Goal:** 

District Goal: 23-JUL-2002

Applicant:

GILEAD

**Brand Name:** 

(ADEFOVIR DIPIVOXIL)

333 LAKESIDE DR

Established Name:

Generic Name: ADEFOVIR DIPIVOXIL

**10MG TABLETS** 

Dosage Form:

TAB (TABLET)

Strength:

10 MG

FDA Contacts:

M. HOLLOMAN (HFD-530)

301-827-2335 , Project Manager

K. LO

(HFD-530)

301-827-2397 , Review Chemist

S. MILLER

(HFD-530)

301-827-2392 , Team Leader

Overall Recommendation:

ACCEPTABLE on 09-SEP-2002 by J. D AMBROGIO (HFD-324) 301-827-0062

Establishment: 2952384

**GILEAD SCIENCES INC** 

DMF No:

AADA No:

346 LAKESIDE DR

**FOSTER CITY, CA 94404** 

Profile: CTL

OAI Status: NONE

Last Milestone: OC RECOMMENDATION

Milestone Date: 09-SEP-2002

Decision:

**ACCEPTABLE** 

Reason:

DISTRICT RECOMMENDATION

Responsibilities: DRUG SUBSTANCE RELEASE

**TESTER** 

FINISHED DOSAGE RELEASE

FINISHED DOSAGE STABILITY

TESTER-

Establishment:

DMF No:

AADA No:

Responsibilities:

Profile: CTL

OAI Status: NONE

Last Milestone: OC RECOMMENDATION

Decision:

Milestone Date: 03-MAY-2002

Reason:

**ACCEPTABLE** 

**BASED ON PROFILE** 

Establishment:

DMF No:

AADA No:

Profile: TCM

OAI Status: NONE

Last Milestone: OC RECOMMENDATION

Milestone Date: 08-MAY-2002

Responsibilities:

### FDA CDER EES ESTABLISHMENT EVALUATION REQUEST **SUMMARY REPORT**

Decision:

**ACCEPTABLE** 

Reason:

**DISTRICT RECOMMENDATION** 

Establishment:

DMF No:

AADA No:

Profile: CTL

OAI Status: NONE

Responsibilities:

Last Milestone: OC RECOMMENDATION

Decision:

Milestone Date: 06-MAY-2002 **ACCEPTABLE** 

Reason:

**BASED ON PROFILE** 

Establishment:

DMF No:

AADA No:

Profile: CSN

OAI Status: NONE

Responsibilities:

Last Milestone: OC RECOMMENDATION

Milestone Date: 04-SEP-2002

Decision:

**ACCEPTABLE** 

Reason:

DISTRICT RECOMMENDATION

Establishment:

DMF No:

AADA No:

Profile: CSN

OAI Status: NONE

Responsibilities:

Last Milestone: OC RECOMMENDATION

Milestone Date: 08-MAY-2002

Decision:

**ACCEPTABLE** 

Reason:

DISTRICT RECOMMENDATION